DYNAMIKA™ Platform: Imaging In Clinical Trials

Discover how IAG’s DYNAMIKA™, an AI-enabled imaging platform for clinical trials, accelerates study timelines, enhances data quality, and delivers regulatory-ready imaging endpoints across oncology, immunology, and neurology research.

Today’s clinical trials are a race against complexity. As therapeutic areas become more specialized, and as multi-regional studies demand flawless coordination, the pressure to accelerate timelines without sacrificing data quality is intense.

The traditional methods of managing central imaging, often fragmented, manual, and prone to delays, are no longer fit for purpose. Innovation isn’t optional; it’s the definitive path to industry leadership and faster patient outcomes.

For biopharma executives, clinical trial researchers, and key stakeholders, the challenge is clear: how do you harmonize global imaging data, integrate next-generation analytics, and ensure every endpoint is regulatory-ready, all within a single, secure ecosystem?

The answer lies in using smarter technology as an enabler to enhance the speed and accuracy of clinical trial protocols.

IAG’s proprietary platform, DYNAMIKA™, for instance, is not merely a data viewer or a siloed software tool; it is a future-forward, cloud-native enterprise solution designed to fundamentally improve the management and analysis of medical imaging in drug development. Developed by an expert imaging CRO, the platform unifies the entire imaging workflow, turning complex data logistics into a core competitive advantage.

DYNAMIKA™ serves as the single source of truth for all imaging data in a trial, from Phase I through post-marketing studies, including critical real-world evidence (RWE) initiatives.

The platform’s core architecture delivers on the promise of operational excellence, providing a robust, scalable infrastructure that handles data from global sites with efficiency and compliance. This end-to-end management approach is crucial for modern, decentralized trials.

What truly sets DYNAMIKA™ apart is its deep integration of Artificial Intelligence (AI). We view AI not as a separate tool, but as an embedded co-pilot for advanced image analysis. The platform is purpose-built to leverage AI imaging models and machine learning algorithms to generate objective, quantifiable data that traditional qualitative reads often miss.

This level of detail is delivered by providing standardized image assessments across a spectrum of therapeutic indications for smarter decisions, quicker studies, and reliable trial endpoints. Whether in complex oncology trials, rapidly evolving immunology research, or nuanced neurology studies, the platforms AI-powered analytics ensure that every measurement is reproducible, objective, and globally consistent, driving the precision required for personalized medicine.

In the high-stakes world of drug development, speed and compliance must go hand-in-hand. DYNAMIKA™ is engineered to drastically improve trial efficiency by transforming labor-intensive processes into automated, auditable workflows by:

• Accelerated Radiological Reading: Speeds up the central review process.
• Automation of Routine Tasks: Supports expert readers by handling repetitive, administrative work.
• Instant Discrepancy Flagging: Immediately identifies potential issues to maintain quality.
• Minimized Inter-Reader Variability: Ensures consistency and standardization across all expert reviews.
• Real-Time Visibility and Central Monitoring: Allows stakeholders to instantly track site and reader performance.
• Empowers Timely, Informed Decisions: Facilitates quick assessments, including critical go/no-go decisions.
• Eliminates Cycle Completion Delays: Enables decision-making without waiting for traditional, long review cycles.

IAG’s technology is developed in compliance with global standards, including 21 CFR Part 11 and ISO 13485, certifying its infrastructure is built for ultimate data security and compliance. This focus on meticulous regulatory readiness means the imaging endpoints delivered are reliably regulator-ready, AI-enabled trial processes.

A powerful platform is only as effective as the expertise behind it. IAG is an imaging CRO that couples DYNAMIKA™ with a global network of radiology and therapeutic experts. These seasoned professionals are deeply integrated into the platform’s workflow, designing custom clinical trial protocols based on specific trial requirements, overseeing data quality, and performing expert central review.

This combination of proprietary technology and human scientific insight means IAG can deploy advanced methodologies in real-time, leveraging the platform’s flexibility to support innovative trial designs, such as umbrella and basket trials. This integrated approach ensures that the output is not just data, but actionable evidence that strengthens a product’s value story.

The advanced imaging platform is a strategic enabler for life sciences companies committed to pushing the boundaries of therapeutic innovation. It consolidates the required elements for successful imaging trials: global data logistics, state-of-the-art imaging analytics, and regulatory integrity.

By choosing a platform that is already ahead of the curve, sponsors gain an immediate operational and scientific edge. It empowers biopharma to leverage the full potential of clinical trial imaging, moving faster, minimizing risk, and delivering novel therapies to patients with greater confidence and speed.

You can learn more about how IAG delivers standardized image assessments across a spectrum of therapeutic indications for reliable trial endpoints, take a look at this video or reach out to our team.